Breaks Categories: News

ThursdayDec 19, 2024 10:33 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility to Advance Neurodegenerative Disease Treatments

Clene (NASDAQ: CLNN) has announced a $10 million debt facility with three affiliated entities, set to close by December 20, 2024. The 18-month secured, partially convertible note carries a 12% fixed interest rate, with an interest-only period for the first year. Sixty-five percent of the note is convertible into common stock at $5.67 per share, a 130% premium over the stock’s signing day closing price. Proceeds will support Clene’s development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval. The company also aims to repay its prior $7.9 million Loan Agreement with Avenue Venture…

Continue Reading

WednesdayDec 18, 2024 3:02 pm

BioMedNewsBreaks — Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan

Lantern Pharma (LTRN)  has enrolled and dosed its first patient in Taiwan for the Phase 2 HARMONIC™ trial evaluating LP-300 in never-smokers with non-small cell lung cancer (“NSCLC”) who have relapsed after tyrosine kinase inhibitor (“TKI”) treatment. This expansion into Asia addresses the region's higher prevalence of never-smoker NSCLC cases, with Taiwan being a key area as over half of lung cancer diagnoses there occur in never-smokers. The trial, conducted across sites in the U.S., Japan, and Taiwan, aims to enroll 90 patients to assess progression-free survival (“PFS”) and overall survival (“OS”) outcomes. Lantern highlighted promising preliminary results, including an…

Continue Reading

TuesdayDec 17, 2024 10:33 am

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Launches $2 Million Share Repurchase Program Amid Record Revenue Growth

NextPlat (NASDAQ: NXPL, NXPLW) announced its Board of Directors has approved a share repurchase program of up to $2 million in outstanding common stock. The timing and execution of repurchases will be at the Company's discretion, with flexibility to utilize open market or privately negotiated transactions. NextPlat expects to achieve record 2024 annual revenue exceeding $63 million, a 70% increase over 2023, driven by growth in satellite connectivity products, recurring airtime revenue, and healthcare contributions. CEO Charles M. Fernandez emphasized the company’s focus on double-digit revenue growth and positive operating cashflows in 2025, supported by a strong balance sheet, as…

Continue Reading

MondayDec 16, 2024 11:01 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary

Scinai Immunotherapeutics (NASDAQ: SCNI) has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Organization (CDMO) operations and address the growing demand for early-stage biologics development in the U.S. Operating from a cGMP-compliant facility in Jerusalem, Israel, Scinai Bioservices has supported nine biotech companies since its 2024 launch and recently signed its first U.S. customer, Serpin Pharma. The new subsidiary will provide boutique CDMO services tailored to early-stage biotech startups, leveraging U.S. grant funding opportunities while addressing concerns related to the BIOSECURE Act. Scinai anticipates significant growth in its CDMO revenues and reputation in the…

Continue Reading

MondayDec 16, 2024 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data transmitted to physicians for timely review and action. This milestone marks the first FDA-cleared device of its kind and lays the foundation for future advancements, including synthesized 12-lead ECGs, AI-driven arrhythmia detection, and heart attack risk assessment. HeartBeam aims to transform cardiac care by delivering actionable insights and predictive diagnostics for patients and physicians globally. To view the full press…

Continue Reading

FridayDec 13, 2024 3:08 pm

BioMedNewsBreaks — Jackson Acquisition Company II (NYSE: JACS.U) Announces Closing of IPO

Jackson Acquisition Company (NYSE: JACS.U) has closed its initial public offering of 23,000,000 units at $10.00 per unit. According to the announcement, the offering size reflects the full exercise of the underwriter’s over-allotment option. The units began trading on the New York Stock Exchange under the ticker symbol JACS.U on Dec. 10, 2024. Each unit consists of one Class A ordinary share and one right to receive one-tenth (1/10) of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are…

Continue Reading

ThursdayDec 12, 2024 12:04 pm

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies

Telomir Pharmaceuticals (NASDAQ: TELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The funding supports Telomir’s innovative pipeline, led by its breakthrough compound, Telomir-1, which has demonstrated preclinical efficacy in reversing age-related conditions, including Type 2 diabetes, by addressing root causes like oxidative stress and telomere shortening. Telomir is also advancing research in Alzheimer’s, cancer, osteoarthritis, and Wilson…

Continue Reading

WednesdayDec 11, 2024 8:45 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Three-Year State Government Contract for Outfitter Satellite Connectivity Services

NextPlat (NASDAQ: NXPL, NXPLW)  announced that its U.S.-based connectivity division, Outfitter Satellite Inc., has been awarded a three-year contract by a U.S. state government to provide satellite connectivity services. The agreement includes satellite airtime service plans and hardware to support the government workforce during remote operations and natural disasters, with an option to extend for two additional years. Outfitter, acquired by NextPlat in April 2024, has over two decades of experience delivering satellite-based connectivity solutions and has generated significant recurring revenue from its services across North America. David Phipps, President of NextPlat, highlighted Outfitter’s role in driving domestic growth and its…

Continue Reading

TuesdayDec 10, 2024 2:40 pm

BioMedNewsBreaks — Adageis Engages IBN for Corporate Communications Expertise

  Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative value-based care solutions. Through integrating artificial intelligence (“AI”) and machine learning, Adageis’ Patented Risk Engine (“PRE”) transforms healthcare delivery, equipping providers with tools to enable value-based care, improve patient outcomes, and increase operational efficiency. The company’s flagship ProActive Care Platform integrates with existing electronic medical records (“EMR”) systems, offering a seamless, AI-powered solution. Adageis has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts. As part of the client partner relationship, IBN will generate greater…

Continue Reading

TuesdayDec 10, 2024 1:40 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Launches Xcellara(TM) — an Innovative Supplement That Harnesses Nature for Optimal Health

BioAdaptives (OTC: BDPT) today announced the launch of Xcellara(TM) Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary potential of stem cells' regeneration power through a blend of adaptogens, herbs and beneficial bacteria. The innovative formulation supports the body's natural repair mechanisms, promoting anti-aging and enhancing overall health and wellness. "This is an exciting milestone for BioAdaptives as we continue to push the boundaries of what's possible in natural health supplements," said the company’s CEO James Keener. "With the launch of Xcellara(TM) Stem Cell Activator, we're offering a product that's both innovative and deeply rooted in science, leveraging a…

Continue Reading